- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02325050
A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants
June 12, 2017 updated by: Janssen Vaccines & Prevention B.V.
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind Study to Evaluate the Safety, Tolerability and Immunogenicity of Heterologous and Homologous Prime-Boost Regimens Using MVA-BN-Filo® and Ad26.ZEBOV Administered in Different Doses, Sequences and Schedules in Healthy Adult Subjects
The purpose of this study is to test the safety and immunogenicity of MVA-BN-Filo and Ad26.ZEBOV as heterologous and homologous prime-boost vaccine regimens in healthy adult participants.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study consists of 3 parts: the first and third part with standard doses and the second part with higher doses.
All parts are randomized, placebo-controlled, observer-blind to evaluate the safety, tolerability and immunogenicity of MVA-BN-Filo and Ad26.ZEBOV administered in different doses, sequences and schedules to healthy adult participants.
The study consists of a screening period of up to 28 days, a vaccination period in which participants will be vaccinated at baseline (Day 1) followed by a boost on Day 15, 29, or 57, and third vaccine 1-year post-prime (3rd vaccination is optional for subjects in groups 1-8).
The total duration of the study will be about 1 year for participants who wiil receive boost vaccine and about 3 months for participants who will receive placebo and 2 year for participants who will receive a 3rd dose.
Safety will be monitored during the study.
Study Type
Interventional
Enrollment (Actual)
164
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Rockville, Maryland, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Must be healthy on the basis of physical examination, medical history, and the investigator's clinical judgment
- Have a body mass index (BMI) ≥18.5 and <35.0 kg/m2
- Women of childbearing potential must have a negative serum β-human chorionic gonadotropin pregnancy test at screening, a negative urine pregnancy test immediately prior to each study vaccine administration, and practice adequate birth control measures from 28 days before the prime vaccination until at least 3 months after the boost vaccination as specified in the study protocol. If not heterosexually active at screening, must agree to practice adequate birth control measures if they become heterosexually active during their participation in the study (from screening onwards until at least 3 months after the boost vaccination). Agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during participation in the study (from screening onwards until at least 3 months after the boost vaccination)
- Women of non-childbearing potential, defined as postmenopausal (>45 years of age with amenorrhea for ≥2 years or any age with amenorrhea for ≥6 months and serum follicle-stimulating hormone [FSH] >40 mIU/mL) or surgically sterile (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy), are not required to use the birth control methods as specified in the study protocol
- A man who has not had a vasectomy and is sexually active with a woman of childbearing potential must agree to use a double-barrier method of birth control, such as either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository. In case the female partner is using an adequate method of birth control, a single-barrier method of birth control for the male subject is acceptable. Men must also agree not to donate sperm during their participation in the study (from screening onwards until at least 3 months after the boost vaccination)
- Must be available and willing to participate for the duration of the study visits and follow-up, provide verifiable identification, and have a means to be contacted
Exclusion Criteria:
- Has been vaccinated with a candidate Ebola vaccine
- Has been diagnosed with Ebola disease or exposed to Ebola including travel to West Africa in the last 12 months. West Africa includes but is not limited to the countries of Guinea, Liberia, Mali, and Sierra Leone. Participants who anticipate traveling to epidemic Ebola areas before the start of the long-term follow-up period will also be excluded from enrollment into the study
- Has received any Ad26- or MVA-based candidate vaccine in the past
- Known allergy or history of anaphylaxis or other serious adverse reactions to vaccines or vaccine products (including any of the constituents of the study vaccines), including known allergy to egg or aminoglycosides
- A woman who is pregnant or breast-feeding, or planning to become pregnant while enrolled in the study or within 3 months after the boost vaccination
- History of diabetes mellitus type 1 or type 2, including cases controlled with diet alone; thyroidectomy, or thyroid disease requiring medication during the last 12 months; uncontrolled hypertension as defined in the study protocol; or, major psychiatric illness and/or substance abuse problems during the past 12 months that in the opinion of the investigator would preclude participation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1
Participants will receive MVA-BN-Filo/ Ad26.ZEBOV (Day 1 /Day 15) or Placebo (Day 1/Day 15).
Participants will receive Ad26.ZEBOV (5x10^10 vp) on Day 360.
|
One 0.5 milliliter (ml) intramuscular (IM) injection of 1*10^8, (50%Tissue Culture Infectious Dose [TCID50]).
One 0.5 mL IM injection of 5*10^10 viral particles (vp).
One 0.5 milliliter (ml) intramuscular (IM) injection of 4.4*10^8, (50%Tissue Culture Infectious Dose [TCID50]).
One 0.5 mL IM injection of 1*10^11 viral particles (vp).
One 0.5 mL IM injection of 0.9% saline.
|
Experimental: Group 2
Participants will receive MVA-BN-Filo/Ad26.ZEBOV (Day 1 /Day 29) or placebo (Day 1/Day 29).
Participants will receive Ad26.ZEBOV (5x10^10 vp) on Day 360.
|
One 0.5 milliliter (ml) intramuscular (IM) injection of 1*10^8, (50%Tissue Culture Infectious Dose [TCID50]).
One 0.5 mL IM injection of 5*10^10 viral particles (vp).
One 0.5 milliliter (ml) intramuscular (IM) injection of 4.4*10^8, (50%Tissue Culture Infectious Dose [TCID50]).
One 0.5 mL IM injection of 1*10^11 viral particles (vp).
One 0.5 mL IM injection of 0.9% saline.
|
Experimental: Group 3
Participants will receive MVA-BN-Filo /Ad26.ZEBOV/ (Day 1/Day 57) or placebo (Day 1/Day 57).
Participants will receive Ad26.ZEBOV (5x10^10 vp) on Day 360.
|
One 0.5 milliliter (ml) intramuscular (IM) injection of 1*10^8, (50%Tissue Culture Infectious Dose [TCID50]).
One 0.5 mL IM injection of 5*10^10 viral particles (vp).
One 0.5 milliliter (ml) intramuscular (IM) injection of 4.4*10^8, (50%Tissue Culture Infectious Dose [TCID50]).
One 0.5 mL IM injection of 1*10^11 viral particles (vp).
One 0.5 mL IM injection of 0.9% saline.
|
Experimental: Group 4
Participants will receive Ad26.ZEBOV/ MVA-BN-Filo (Day 1/Day 29) or placebo (Day 1/Day 29).
Participants will receive Ad26.ZEBOV (5x10^10 vp) on Day 360.
|
One 0.5 milliliter (ml) intramuscular (IM) injection of 1*10^8, (50%Tissue Culture Infectious Dose [TCID50]).
One 0.5 mL IM injection of 5*10^10 viral particles (vp).
One 0.5 milliliter (ml) intramuscular (IM) injection of 4.4*10^8, (50%Tissue Culture Infectious Dose [TCID50]).
One 0.5 mL IM injection of 1*10^11 viral particles (vp).
One 0.5 mL IM injection of 0.9% saline.
|
Experimental: Group 5
Participants will receive MVA-BN-Filo (Day 1 and Day 15) or placebo (Day 1 and Day 15).
Participants will receive Ad26.ZEBOV (5x10^10 vp) on Day 360.
|
One 0.5 milliliter (ml) intramuscular (IM) injection of 1*10^8, (50%Tissue Culture Infectious Dose [TCID50]).
One 0.5 mL IM injection of 5*10^10 viral particles (vp).
One 0.5 milliliter (ml) intramuscular (IM) injection of 4.4*10^8, (50%Tissue Culture Infectious Dose [TCID50]).
One 0.5 mL IM injection of 1*10^11 viral particles (vp).
One 0.5 mL IM injection of 0.9% saline.
|
Experimental: Group 6
Participants will receive Ad26.ZEBOV (Day 1 and Day 15) or placebo (Day 1 and Day 15).
Participants will receive MVA-BN-Filo (1*10^8 TCID50) on Day 360.
|
One 0.5 milliliter (ml) intramuscular (IM) injection of 1*10^8, (50%Tissue Culture Infectious Dose [TCID50]).
One 0.5 mL IM injection of 5*10^10 viral particles (vp).
One 0.5 milliliter (ml) intramuscular (IM) injection of 4.4*10^8, (50%Tissue Culture Infectious Dose [TCID50]).
One 0.5 mL IM injection of 1*10^11 viral particles (vp).
One 0.5 mL IM injection of 0.9% saline.
|
Experimental: Group 7
Participants will receive Ad26.ZEBOV/ MVA-BN-Filo (Day 1/Day 15) or Placebo (Day 1/Day 15).
Participants will receive Ad26.ZEBOV (5x10^10 vp) on Day 360.
|
One 0.5 milliliter (ml) intramuscular (IM) injection of 1*10^8, (50%Tissue Culture Infectious Dose [TCID50]).
One 0.5 mL IM injection of 5*10^10 viral particles (vp).
One 0.5 milliliter (ml) intramuscular (IM) injection of 4.4*10^8, (50%Tissue Culture Infectious Dose [TCID50]).
One 0.5 mL IM injection of 1*10^11 viral particles (vp).
One 0.5 mL IM injection of 0.9% saline.
|
Experimental: Group 8
Participants will receive Ad26.ZEBOV/ MVA-BN-Filo (Day 1 /Day 29) or Placebo (Day 1/Day 29).
Participants will receive Ad26.ZEBOV (1x10^11 vp) on Day 360.
|
One 0.5 milliliter (ml) intramuscular (IM) injection of 1*10^8, (50%Tissue Culture Infectious Dose [TCID50]).
One 0.5 mL IM injection of 5*10^10 viral particles (vp).
One 0.5 milliliter (ml) intramuscular (IM) injection of 4.4*10^8, (50%Tissue Culture Infectious Dose [TCID50]).
One 0.5 mL IM injection of 1*10^11 viral particles (vp).
One 0.5 mL IM injection of 0.9% saline.
|
Experimental: Group 9
Participants will receive MVA-BN-Filo/ Ad26.ZEBOV (Day 1 /Day 8) or Placebo (Day 1/Day 8).
|
One 0.5 milliliter (ml) intramuscular (IM) injection of 1*10^8, (50%Tissue Culture Infectious Dose [TCID50]).
One 0.5 mL IM injection of 5*10^10 viral particles (vp).
One 0.5 milliliter (ml) intramuscular (IM) injection of 4.4*10^8, (50%Tissue Culture Infectious Dose [TCID50]).
One 0.5 mL IM injection of 1*10^11 viral particles (vp).
One 0.5 mL IM injection of 0.9% saline.
|
Experimental: Group 10
Participants will receive MVA-BN-Filo/ Ad26.ZEBOV (Day 1 /Day 15) or Placebo (Day 1/Day 15).
|
One 0.5 milliliter (ml) intramuscular (IM) injection of 1*10^8, (50%Tissue Culture Infectious Dose [TCID50]).
One 0.5 mL IM injection of 5*10^10 viral particles (vp).
One 0.5 milliliter (ml) intramuscular (IM) injection of 4.4*10^8, (50%Tissue Culture Infectious Dose [TCID50]).
One 0.5 mL IM injection of 1*10^11 viral particles (vp).
One 0.5 mL IM injection of 0.9% saline.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with reactogenicity (ie, solicited local and systemic adverse events)
Time Frame: 1 week after each study vaccine administration
|
1 week after each study vaccine administration
|
Number of participants with adverse events
Time Frame: Up to 21 days after the last vaccination (up to Day 381)
|
Up to 21 days after the last vaccination (up to Day 381)
|
Number of participants with serious adverse events
Time Frame: Up to the end of long term follow-up (up to Day 720)
|
Up to the end of long term follow-up (up to Day 720)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Immune responses to the study vaccine regimens as measured by a virus neutralization assay
Time Frame: up to Day 720 (Group 1-8); Day 360 (Group 9, 10)
|
up to Day 720 (Group 1-8); Day 360 (Group 9, 10)
|
Immune responses to the study vaccine regimens as measured by an enzyme-linked immunosorbent assay (ELISA)
Time Frame: up to Day 720 (Group 1-8); Day 360 (Group 9, 10)
|
up to Day 720 (Group 1-8); Day 360 (Group 9, 10)
|
Immune responses to the study vaccine regimens as measured by an enzyme-linked immunospot (ELISpot) assay
Time Frame: up to Day 720 (Group 1-8); Day 360 (Group 9, 10)
|
up to Day 720 (Group 1-8); Day 360 (Group 9, 10)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 8, 2015
Primary Completion (Actual)
July 2, 2015
Study Completion (Actual)
May 8, 2017
Study Registration Dates
First Submitted
December 19, 2014
First Submitted That Met QC Criteria
December 19, 2014
First Posted (Estimate)
December 24, 2014
Study Record Updates
Last Update Posted (Actual)
June 14, 2017
Last Update Submitted That Met QC Criteria
June 12, 2017
Last Verified
June 1, 2017
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- CR106479
- VAC52150EBL1002 (Other Identifier: Janssen Vaccines & Prevention B.V.)
Drug and device information, study documents
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on MVA-BN-Filo
-
Janssen Vaccines & Prevention B.V.National Institute of Allergy and Infectious Diseases (NIAID)Completed
-
MRC/UVRI and LSHTM Uganda Research UnitEpicentre, Paris, France.; Janssen Pharmaceutica N.V., Belgium; Coalition for... and other collaboratorsCompleted
-
University of OxfordNational Institute of Allergy and Infectious Diseases (NIAID); Wellcome TrustCompletedEbola | Ebola ZaireUnited Kingdom
-
Janssen Vaccines & Prevention B.V.Institut National de la Santé Et de la Recherche Médicale, France; Centre Muraz and other collaboratorsCompletedHemorrhagic Fever, EbolaKenya, Uganda, Burkina Faso, Côte D'Ivoire
-
Janssen Vaccines & Prevention B.V.Walter Reed Army Institute of Research (WRAIR)CompletedHemorrhagic Fever, EbolaUnited States, Uganda, Kenya, Mozambique, Nigeria, Tanzania
-
Crucell Holland BVCompleted
-
London School of Hygiene and Tropical MedicinePublic Health England; Janssen Vaccines & Prevention B.V.; Epicentre; Coalition... and other collaboratorsActive, not recruitingEbola Virus DiseaseCongo, The Democratic Republic of the
-
Janssen Vaccines & Prevention B.V.Institut National de la Santé Et de la Recherche Médicale, France; University...CompletedEbola Viral DiseaseFrance, United Kingdom
-
Janssen Vaccines & Prevention B.V.Emory University; Coalition for Epidemic Preparedness Innovations; Center for...Completed
-
Crucell Holland BVCompleted